Filament Health has collaborated with University College London (UCL) in the UK to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.
These trials, approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), aim to investigate the impacts of the drug on the function, perception, and psychological well-being of the brain.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The first randomised controlled trial will assess the impact of a 21-day self-guided programme, Digital Intervention for Psychedelic Preparation.
This programme is designed to improve the therapeutic results of psychedelic experiences.
Subjects will be randomly assigned to either a meditation-based intervention or a control condition based on music, both delivered via the same digital platform.
After completing the programme, subjects will receive 25mg of the drug in a supervised session at the university.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe trial will evaluate how the different preparatory strategies impact the quality of the psychedelic experience, psychological readiness levels, and changes in mental well-being.
The study will also assess intervention adherence, engagement of the user, and the digital platform’s acceptability, which are said to inform the design of upcoming efficacy studies.
The second study will investigate the way in which low doses of psilocybin influence the perception of pareidolia and geometric hallucinations.
It builds on models of excitatory visual cortex dynamics and will evaluate low-dose, psilocybin-induced neural excitation interaction with external sensory input to form hallucinatory experiences under regulated conditions.
UCL professor and the trials’ principal investigator Dr Jeremy I Skipper said: “We will examine both how preparation methods influence therapeutic and cognitive outcomes, and how psilocybin interacts with sensory and cognitive systems to shape perception.
“Together, these studies offer valuable insight into the therapeutic potential and fundamental mechanisms of psychedelic compounds. They would not be possible without the support of Filament Health.”
